- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:00 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 320 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen | |
| Mo | Elicera Therapeutics AB: Elicera publishes information document regarding the rights issue | 217 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics carries out a rights issue of approximately SEK 73 million | 139 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026 | 104 | GlobeNewswire (Europe) | First quarter (January-March 2026)
Operating profit/loss amounted to SEK -5,116,779 (-8,069,404).
Loss for the period amounted to SEK -5,060,060 (-8,013,462).
Cash flow from operating activities... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics AB: Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu | 200 | GlobeNewswire (Europe) | Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.03. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate | 156 | GlobeNewswire (Europe) | Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 10.03. | Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden) | 1 | Cision News | ||
| 06.03. | Elicera Therapeutics AB: Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients | 195 | GlobeNewswire (Europe) | Gothenburg, March 6, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 27.02. | Elicera Therapeutics AB: Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway | 1.035 | GlobeNewswire (Europe) | Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today... ► Artikel lesen | |
| 18.02. | Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference | 4 | Cision News | ||
| 13.02. | Elicera Therapeutics AB Q4 Loss Widens | 1 | RTTNews | ||
| 13.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025 | 168 | GlobeNewswire (Europe) | Fourth quarter (October-December 2025)
Operating loss amounted to o SEK -7,129,626 (-2,911,958).
Loss for the period amounted to SEK -6,965,286 (-2,603,242).
Cash flow from operating activities... ► Artikel lesen | |
| 11.02. | Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study | 1 | Cision News | ||
| 22.01. | Elicera Therapeutics' CSO invited to present at multiple scientific conferences | 1 | Cision News | ||
| 09.01. | Elicera Therapeutics AB: Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors | 202 | GlobeNewswire (Europe) | Gothenburg, January 9, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 23.12.25 | Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 1 | Cision News | ||
| 14.11.25 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025 | 162 | GlobeNewswire (Europe) | Third quarter (July-September 2025)
Operating loss amounted to SEK 146,689 (-2,697,267).
Loss for the period amounted to SEK 304,153 (-2,514,629).
Cash flow from operating activities totaled SEK... ► Artikel lesen | |
| 13.11.25 | Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research | 1 | Cision News | ||
| 19.09.25 | Elicera Therapeutics AB: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 241 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 29.08.25 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 267 | GlobeNewswire (Europe) | Second quarter (April-June 2025)
Operating loss amounted to SEK -2,892,341 (-5,841,409).
Loss for the period amounted to SEK -2,732,070 (-5,622,779).
Cash flow from operating activities totaled... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,080 | -2,31 % | Evotec im Umbau: Verlust steigt, Strategie-Prüfung läuft | Das Biotech-Unternehmen Evotec erzielte im ersten Quartal 2026 einen Konzernumsatz von 156,6 Millionen Euro, nach knapp 200 Millionen Euro im Vorjahreszeitraum. Der Rückgang erklärt sich nach ANgaben... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 613,60 | +1,40 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| BRAIN BIOTECH | 3,230 | -3,58 % | BRAIN BIOTECH AG zeigt fundamentale Stärke | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 1,146 | +1,06 % | Cardiol Therapeutics Inc: Cardiol to publish phase II Maveric results in JAHA | ||
| CSL | 61,15 | -2,13 % | CSL's Big Write-Down Halves Broker Forecasts | ||
| BURCON NUTRASCIENCE | 1,210 | -3,20 % | Burcon NutraScience Corporation: Burcon Announces Appointment of New Director | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| MANNKIND | 2,942 | +2,94 % | MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -2,53 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,378 | +3,45 % | Oxford Nanopore Tech - Director/PDMR Shareholding | ||
| ADAPTIMMUNE THERAPEUTICS | 0,007 | -50,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 2,132 | -4,57 % | Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end | ||
| CORMEDIX | 6,590 | +1,38 % | CorMedix, Inc.: CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 | ||
| TELO GENOMICS | 0,008 | 0,00 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 5,510 | +3,18 % | Aligos Therapeutics GAAP EPS of -$2.21 beats by $0.04, revenue of $2.83M beats by $2.5M |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,002 (-0,57 %) liegt der Kurs bei 0,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.